Udit Batra is Chief Executive Officer of MilliporeSigma, the €6.2 billion Life Science business of Merck KGaA, Darmstadt, Germany and a member of its Executive Board. In addition to leading MilliporeSigma, Udit has Board responsibility for the company’s global Business Technology function and the company’s Bioethics Advisory Panel.
Born in New Delhi, India, Udit is an accomplished executive who has dedicated his career to improving health for people globally, bringing more than 20 years’ experience in healthcare and the life sciences. After Udit became CEO in 2014, he and his MilliporeSigma team developed and executed a growth strategy that included the 2015 acquisition of chemicals and technology giant Sigma-Aldrich. Udit architected and led this merger — the largest acquisition in the history of Merck KGaA, Darmstadt, Germany and the largest ever in the life science industry. Before joining MilliporeSigma, Udit led the turnaround of the Merck KGaA, Darmstadt, Germany’s consumer health business and worked in the pharmaceutical industry in R&D, Strategy, and general management at Merck & Co., Kenilworth, NJ, McKinsey and Novartis. He holds both a PhD and BS in chemical engineering from Princeton University and the University of Delaware, respectively.
Since 2015, MilliporeSigma has set the performance benchmark in the industry with the fastest organic sales growth and a profit margin that is 400-500 basis points ahead of other large peers. Additionally, MilliporeSigma is an innovation leader with solid positions in areas such as tools for gene editing, manufacturing of novel modalities such as viral vectors for cell and gene therapy, and in digital commercial models such as e-commerce.
Today, Udit continues to lead the business through a strategic transformation that has made MilliporeSigma a top-three player in the industry and an employer of choice in many regions where it operates around the world.